The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | KarMMa: idecabtagene vicleucel QoL
Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, discusses results from the KarMMa trial (NCT03361748) which investigated the quality of life in patients with relapsed and refractory multiple myeloma treated with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
